FDA Drug Recalls

Recalls / Class III

Class IIID-0236-2026

Product

Cisatracurium Besylate Injection USP, 10 mg/5 mL* (2mg/mL), 10 x 5 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single-dose 5 mL vial NDC 70069-141-01; 10x5 mL single dose vial per Carton NDC 70069-141-10.

Brand name
Cisatracurium Besylate
Generic name
Cisatracurium Besylate
Active ingredient
Cisatracurium Besylate
Route
Intravenous
NDCs
70069-141, 70069-151
FDA application
ANDA206791
Affected lot / code info
Lot#: A240438, Exp Date 1/31/26, A250125, Exp Date 8/31/26

Why it was recalled

Subpotent product:out of specification assay results observed during long term stability testing.

Recalling firm

Firm
SOMERSET THERAPEUTICS LLC
Manufacturer
Somerset Therapeutics, LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
300 Franklin Square Dr, Somerset, New Jersey 08873-4187

Distribution

Quantity
52,340 5mL vials
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2025-11-26
FDA classified
2025-12-15
Posted by FDA
2025-12-24
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0236-2026. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: Cisatracurium Besylate · FDA Drug Recalls